Goodwin

Goodwin’s global practice advises biotech, pharma, and healthcare companies, along with life science venture capital and investment firms. The growing practice supports clients in matters as wide-ranging as regulatory compliance, IP and M&A. The team’s representation of Prime Medicine in its $3.5bn deal with Bristol Myers Squibb evidences its excellence in research collaboration and license agreement matters. The practice is headed by Kingsley Taft, vastly experienced in commercial, financing and capital market transactions, and Mitchell Bloom, who specializes in emerging companies and life sciences investors. Both in Boston, transactional lawyer Robert Puopolo and Marishka DeToy, who focuses on capital markets and corporate matters, are key figures in the practice. In DC, Steven Tjoe focuses on product development strategies and FDA regulatory counseling. Arriving on the Boston-based team from Cooley LLP are Joshua Rottner, venture capital and growth equity funds specialist, and Michael McGrail, focused on medical devices and life sciences. Other key hires include litigation expert Michael Siekman, arriving in Boston from McDermott Will & Emery LLP, M&A specialist Amanda Gill, from Paul, Weiss, Rifkind, Wharton & Garrison LLP, and IP lawyer Carl Morales, from Fenwick & West LLP; the latter two are based in New York.